combining antigen-specific vaccination and targeted radionuclide therapy in a murine prostate model
Published 2 years ago • 51 plays • Length 1:32Download video MP4
Download video MP3
Similar videos
-
5:27
177lu-psma-617 radionuclide therapy in mcrpc
-
3:30
radionuclide conjugates 225ac-j591 and 177lu-psma-i&t for mcrpc
-
2:10
exploring the new frontier: radionuclide therapy in metastatic prostate cancer
-
2:29
dr. tagawa on brca2 in patients with prostate cancer receiving psma-targeted radionuclide therapy
-
1:05
combining a dna vaccine with pembrolizumab for mcrpc
-
0:56
vaccines are a promising direction for prostate cancer immunotherapy
-
4:48
vision: lu-177-psma-617 in mcrpc
-
5:42
immune, hormone, & radiation combined for prostate cancer | ask a prostate expert, mark scholz, md
-
23:26
radionuclide therapy in prostate cancer
-
5:25
developing vaccines as a treatment for prostate cancer
-
15:15
prostate cancer immunotherapy trials
-
2:26
combining prrt with targeted therapy
-
8:29
recurrent and advanced prostate cancer | answering youtube comments #5, the pcri
-
16:30
prostate specific membrane antigen targeted radioligand therapy of metastatic castration resistant p
-
56:52
targeting prostate cancer stem cells with t cell immunotherapy
-
14:39
just the beginning: what's next for radiotheranostics in prostate cancer?
-
1:20:10
new developments in radiopharmaceutical imaging and therapy of prostate cancer - dr. arman rahmim
-
5:12
using lutetium-177 treatment for prostate cancer | ask a prostate expert, mark scholz, md
-
17:05
psma targeting for treatment of advanced prostate cancer - 2021 prostate cancer patient conference